Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth [Seeking Alpha]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Seeking Alpha
Follower s Follow Play 51min Summary Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent study suggests Cushing's Syndrome is more prevalent than believed, leading to a significant expansion of its potential patient base. Corcept has developed Relacorilant as a far safer and more effective drug than its current drug Korlym for Cushing's which has just gone generic. Corcept broke the code defying Major Pharma for years and identified 1000 cortisol modulating compounds to address 17 diverse therapeutics areas with 10 currently in Phases 1, 2 & 3. Despite a patent challenge, Corcept's stock is potentially significantly undervalued, with the company poised for five to 10 years of strong double digit percentage growth in patient count, revenue and earnings. Ca-ssis/iStock via Getty Images Data by YCharts CORT has generated a
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Does Corcept Therapeutics (CORT) Have a Long Runway for Growth? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $38.00 to $67.00. They now have an "overweight" rating on the stock.MarketBeat
- Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors [Yahoo! Finance]Yahoo! Finance
- Corcept Shares Rise More Than 45% in Six Months: Here's Why [Yahoo! Finance]Yahoo! Finance
- Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 7/29/24 - Beat
CORT
Sec Filings
- 9/19/24 - Form 4
- 9/5/24 - Form 4
- 9/5/24 - Form 4
- CORT's page on the SEC website